1uui
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:1uui.gif|left|200px]] | [[Image:1uui.gif|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_1uui", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | | | + | or leave the SCENE parameter empty for the default display. |
| - | | | + | --> |
| - | + | {{STRUCTURE_1uui| PDB=1uui | SCENE= }} | |
| - | + | ||
| - | + | ||
| - | }} | + | |
'''NMR STRUCTURE OF A SYNTHETIC SMALL MOLECULE, RBT158, BOUND TO HIV-1 TAR RNA''' | '''NMR STRUCTURE OF A SYNTHETIC SMALL MOLECULE, RBT158, BOUND TO HIV-1 TAR RNA''' | ||
| Line 19: | Line 16: | ||
==About this Structure== | ==About this Structure== | ||
| - | 1UUI is a [[Single protein]] structure | + | 1UUI is a [[Single protein]] structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1UUI OCA]. |
==Reference== | ==Reference== | ||
| Line 34: | Line 31: | ||
[[Category: Potter, A J.]] | [[Category: Potter, A J.]] | ||
[[Category: Varani, G.]] | [[Category: Varani, G.]] | ||
| - | [[Category: | + | [[Category: Drug design]] |
| - | [[Category: | + | [[Category: Hiv-1]] |
| - | [[Category: | + | [[Category: Inhibitor]] |
| - | [[Category: | + | [[Category: Ligand-rna interaction]] |
| - | [[Category: | + | [[Category: Rna bulge]] |
| - | [[Category: | + | [[Category: Tar rna]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 11:42:41 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 08:42, 3 May 2008
NMR STRUCTURE OF A SYNTHETIC SMALL MOLECULE, RBT158, BOUND TO HIV-1 TAR RNA
Overview
The targeting of RNA for the design of novel anti-viral compounds has until now proceeded largely without incorporating direct input from structure-based design methodology, partly because of lack of structural data, and complications arising from substrate flexibility. We propose a paradigm to explain the physical mechanism for ligand-induced refolding of trans-activation response element (TAR RNA) from human immunodeficiency virus 1 (HIV-1). Based upon Poisson-Boltzmann analysis of the TAR structure, as bound by a peptide derived from the transcriptional activator protein, Tat, our hypothesis shows that two specific electrostatic interactions are necessary to stabilise the conformation. This result contradicts the belief that a single argininamide residue is responsible for stabilising the TAR fold, as well as the conventional wisdom that electrostatic interactions with RNA are non-specific or dominated by phosphates. We test this hypothesis by using NMR and computational methods to model the interaction of a series of novel inhibitors of the in vitro RNA-binding activities for a peptide derived from Tat. A subset of inhibitors, including the bis-guanidine compound rbt203 and its analogues, induce a conformation in TAR similar to that brought about by the protein. Comparison of the interactions of two of these ligands with the RNA and structure-activity relationships observed within the compound series, confirm the importance of the two specific electrostatic interactions in the stabilisation of the Tat-bound RNA conformation. This work illustrates how the use of medicinal chemistry and structural analysis can provide a rational basis for prediction of ligand-induced conformational change, a necessary step towards the application of structure-based methods in the design of novel RNA or protein-binding drugs.
About this Structure
1UUI is a Single protein structure. Full crystallographic information is available from OCA.
Reference
Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic "hot spots"., Davis B, Afshar M, Varani G, Murchie AI, Karn J, Lentzen G, Drysdale M, Bower J, Potter AJ, Starkey ID, Swarbrick T, Aboul-ela F, J Mol Biol. 2004 Feb 13;336(2):343-56. PMID:14757049 Page seeded by OCA on Sat May 3 11:42:41 2008
Categories: Single protein | Aboul-Ela, F. | Afshar, M. | Bower, J. | Davis, B. | Drysdale, M J. | Karn, J. | Lentzen, G. | Murchie, A I.H. | Potter, A J. | Varani, G. | Drug design | Hiv-1 | Inhibitor | Ligand-rna interaction | Rna bulge | Tar rna
